Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian cancer

Rebecca Stone, Keith A. Baggerly, Guillermo N. Armaiz-Pena, Yu Kang, Angela M. Sanguino, Duangmani Thanapprapasr, Heather J. Dalton, Justin Bottsford-Miller, Behrouz Zand, Rehan Akbani, Lixia Diao, Alpa M. Nick, Koen DeGeest, Gabriel Lopez-Berestein, Robert L. Coleman, Susan Lutgendorf, Anil K. Sood

Research output: Contribution to journalArticle

Abstract

This investigation describes the clinical significance of phosphorylated focal adhesion kinase (FAK) at the major activating tyrosine site (Y397) in epithelial ovarian cancer (EOC) cells and tumor-associated endothelial cells. FAK gene amplification as a mechanism for FAK overexpression and the effects of FAK tyrosine kinase inhibitor VS-6062 on tumor growth, metastasis, and angiogenesis were examined. FAK and phospho-FAKY397 were quantified in tumor (FAK-T; pFAK-T) and tumor-associated endothelial (FAK-endo; pFAK-endo) cell compartments of EOCs using immunostaining and qRTPCR. Associations between expression levels and clinical variables were evaluated. Data from The Cancer Genome Atlas were used to correlate FAK gene copy number and expression levels in EOC specimens. The in vitro and in vivo effects of VS-6062 were assayed in preclinical models. FAK-T and pFAK-T overexpression was significantly associated with advanced stage disease and increased microvessel density (MVD). High MVD was observed in tumors with elevated endothelial cell FAK (59%) and pFAK (44%). Survival was adversely affected by FAK-T overexpression (3.03 vs 2.06 y, P = 0.004), pFAK-T (2.83 vs 1.78 y, P <0.001), and pFAK-endo (2.33 vs 2.17 y, P = 0.005). FAK gene copy number was increased in 34% of tumors and correlated with expression levels (P <0.001). VS-6062 significantly blocked EOC and endothelial cell migration as well as endothelial cell tube formation in vitro. VS-6062 reduced mean tumor weight by 56% (P = 0.005), tumor MVD by 40% (P = 0.0001), and extraovarian metastasis (P <0.01) in orthotopic EOC mouse models. FAK may be a unique therapeutic target in EOC given the dual anti-angiogenic and anti-metastatic potential of FAK inhibitors.

Original languageEnglish (US)
Pages (from-to)919-929
Number of pages11
JournalCancer Biology and Therapy
Volume15
Issue number7
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Focal Adhesion Protein-Tyrosine Kinases
Ovarian Neoplasms
Therapeutics
Neoplasms
Endothelial Cells
Microvessels
Gene Dosage
Neoplasm Metastasis
Gene Amplification
Atlases
Tumor Burden
Cell Adhesion
Protein-Tyrosine Kinases
Cell Movement

Keywords

  • Angiogenesis
  • Cancer/molecular biology
  • Metastasis
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Stone, R., Baggerly, K. A., Armaiz-Pena, G. N., Kang, Y., Sanguino, A. M., Thanapprapasr, D., ... Sood, A. K. (2014). Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biology and Therapy, 15(7), 919-929. https://doi.org/10.4161/cbt.28882

Focal adhesion kinase : An alternative focus for anti-angiogenesis therapy in ovarian cancer. / Stone, Rebecca; Baggerly, Keith A.; Armaiz-Pena, Guillermo N.; Kang, Yu; Sanguino, Angela M.; Thanapprapasr, Duangmani; Dalton, Heather J.; Bottsford-Miller, Justin; Zand, Behrouz; Akbani, Rehan; Diao, Lixia; Nick, Alpa M.; DeGeest, Koen; Lopez-Berestein, Gabriel; Coleman, Robert L.; Lutgendorf, Susan; Sood, Anil K.

In: Cancer Biology and Therapy, Vol. 15, No. 7, 2014, p. 919-929.

Research output: Contribution to journalArticle

Stone, R, Baggerly, KA, Armaiz-Pena, GN, Kang, Y, Sanguino, AM, Thanapprapasr, D, Dalton, HJ, Bottsford-Miller, J, Zand, B, Akbani, R, Diao, L, Nick, AM, DeGeest, K, Lopez-Berestein, G, Coleman, RL, Lutgendorf, S & Sood, AK 2014, 'Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian cancer', Cancer Biology and Therapy, vol. 15, no. 7, pp. 919-929. https://doi.org/10.4161/cbt.28882
Stone, Rebecca ; Baggerly, Keith A. ; Armaiz-Pena, Guillermo N. ; Kang, Yu ; Sanguino, Angela M. ; Thanapprapasr, Duangmani ; Dalton, Heather J. ; Bottsford-Miller, Justin ; Zand, Behrouz ; Akbani, Rehan ; Diao, Lixia ; Nick, Alpa M. ; DeGeest, Koen ; Lopez-Berestein, Gabriel ; Coleman, Robert L. ; Lutgendorf, Susan ; Sood, Anil K. / Focal adhesion kinase : An alternative focus for anti-angiogenesis therapy in ovarian cancer. In: Cancer Biology and Therapy. 2014 ; Vol. 15, No. 7. pp. 919-929.
@article{8867fad2425444c5819fe91dd31a3db0,
title = "Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian cancer",
abstract = "This investigation describes the clinical significance of phosphorylated focal adhesion kinase (FAK) at the major activating tyrosine site (Y397) in epithelial ovarian cancer (EOC) cells and tumor-associated endothelial cells. FAK gene amplification as a mechanism for FAK overexpression and the effects of FAK tyrosine kinase inhibitor VS-6062 on tumor growth, metastasis, and angiogenesis were examined. FAK and phospho-FAKY397 were quantified in tumor (FAK-T; pFAK-T) and tumor-associated endothelial (FAK-endo; pFAK-endo) cell compartments of EOCs using immunostaining and qRTPCR. Associations between expression levels and clinical variables were evaluated. Data from The Cancer Genome Atlas were used to correlate FAK gene copy number and expression levels in EOC specimens. The in vitro and in vivo effects of VS-6062 were assayed in preclinical models. FAK-T and pFAK-T overexpression was significantly associated with advanced stage disease and increased microvessel density (MVD). High MVD was observed in tumors with elevated endothelial cell FAK (59{\%}) and pFAK (44{\%}). Survival was adversely affected by FAK-T overexpression (3.03 vs 2.06 y, P = 0.004), pFAK-T (2.83 vs 1.78 y, P <0.001), and pFAK-endo (2.33 vs 2.17 y, P = 0.005). FAK gene copy number was increased in 34{\%} of tumors and correlated with expression levels (P <0.001). VS-6062 significantly blocked EOC and endothelial cell migration as well as endothelial cell tube formation in vitro. VS-6062 reduced mean tumor weight by 56{\%} (P = 0.005), tumor MVD by 40{\%} (P = 0.0001), and extraovarian metastasis (P <0.01) in orthotopic EOC mouse models. FAK may be a unique therapeutic target in EOC given the dual anti-angiogenic and anti-metastatic potential of FAK inhibitors.",
keywords = "Angiogenesis, Cancer/molecular biology, Metastasis, Targeted therapy",
author = "Rebecca Stone and Baggerly, {Keith A.} and Armaiz-Pena, {Guillermo N.} and Yu Kang and Sanguino, {Angela M.} and Duangmani Thanapprapasr and Dalton, {Heather J.} and Justin Bottsford-Miller and Behrouz Zand and Rehan Akbani and Lixia Diao and Nick, {Alpa M.} and Koen DeGeest and Gabriel Lopez-Berestein and Coleman, {Robert L.} and Susan Lutgendorf and Sood, {Anil K.}",
year = "2014",
doi = "10.4161/cbt.28882",
language = "English (US)",
volume = "15",
pages = "919--929",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "7",

}

TY - JOUR

T1 - Focal adhesion kinase

T2 - An alternative focus for anti-angiogenesis therapy in ovarian cancer

AU - Stone, Rebecca

AU - Baggerly, Keith A.

AU - Armaiz-Pena, Guillermo N.

AU - Kang, Yu

AU - Sanguino, Angela M.

AU - Thanapprapasr, Duangmani

AU - Dalton, Heather J.

AU - Bottsford-Miller, Justin

AU - Zand, Behrouz

AU - Akbani, Rehan

AU - Diao, Lixia

AU - Nick, Alpa M.

AU - DeGeest, Koen

AU - Lopez-Berestein, Gabriel

AU - Coleman, Robert L.

AU - Lutgendorf, Susan

AU - Sood, Anil K.

PY - 2014

Y1 - 2014

N2 - This investigation describes the clinical significance of phosphorylated focal adhesion kinase (FAK) at the major activating tyrosine site (Y397) in epithelial ovarian cancer (EOC) cells and tumor-associated endothelial cells. FAK gene amplification as a mechanism for FAK overexpression and the effects of FAK tyrosine kinase inhibitor VS-6062 on tumor growth, metastasis, and angiogenesis were examined. FAK and phospho-FAKY397 were quantified in tumor (FAK-T; pFAK-T) and tumor-associated endothelial (FAK-endo; pFAK-endo) cell compartments of EOCs using immunostaining and qRTPCR. Associations between expression levels and clinical variables were evaluated. Data from The Cancer Genome Atlas were used to correlate FAK gene copy number and expression levels in EOC specimens. The in vitro and in vivo effects of VS-6062 were assayed in preclinical models. FAK-T and pFAK-T overexpression was significantly associated with advanced stage disease and increased microvessel density (MVD). High MVD was observed in tumors with elevated endothelial cell FAK (59%) and pFAK (44%). Survival was adversely affected by FAK-T overexpression (3.03 vs 2.06 y, P = 0.004), pFAK-T (2.83 vs 1.78 y, P <0.001), and pFAK-endo (2.33 vs 2.17 y, P = 0.005). FAK gene copy number was increased in 34% of tumors and correlated with expression levels (P <0.001). VS-6062 significantly blocked EOC and endothelial cell migration as well as endothelial cell tube formation in vitro. VS-6062 reduced mean tumor weight by 56% (P = 0.005), tumor MVD by 40% (P = 0.0001), and extraovarian metastasis (P <0.01) in orthotopic EOC mouse models. FAK may be a unique therapeutic target in EOC given the dual anti-angiogenic and anti-metastatic potential of FAK inhibitors.

AB - This investigation describes the clinical significance of phosphorylated focal adhesion kinase (FAK) at the major activating tyrosine site (Y397) in epithelial ovarian cancer (EOC) cells and tumor-associated endothelial cells. FAK gene amplification as a mechanism for FAK overexpression and the effects of FAK tyrosine kinase inhibitor VS-6062 on tumor growth, metastasis, and angiogenesis were examined. FAK and phospho-FAKY397 were quantified in tumor (FAK-T; pFAK-T) and tumor-associated endothelial (FAK-endo; pFAK-endo) cell compartments of EOCs using immunostaining and qRTPCR. Associations between expression levels and clinical variables were evaluated. Data from The Cancer Genome Atlas were used to correlate FAK gene copy number and expression levels in EOC specimens. The in vitro and in vivo effects of VS-6062 were assayed in preclinical models. FAK-T and pFAK-T overexpression was significantly associated with advanced stage disease and increased microvessel density (MVD). High MVD was observed in tumors with elevated endothelial cell FAK (59%) and pFAK (44%). Survival was adversely affected by FAK-T overexpression (3.03 vs 2.06 y, P = 0.004), pFAK-T (2.83 vs 1.78 y, P <0.001), and pFAK-endo (2.33 vs 2.17 y, P = 0.005). FAK gene copy number was increased in 34% of tumors and correlated with expression levels (P <0.001). VS-6062 significantly blocked EOC and endothelial cell migration as well as endothelial cell tube formation in vitro. VS-6062 reduced mean tumor weight by 56% (P = 0.005), tumor MVD by 40% (P = 0.0001), and extraovarian metastasis (P <0.01) in orthotopic EOC mouse models. FAK may be a unique therapeutic target in EOC given the dual anti-angiogenic and anti-metastatic potential of FAK inhibitors.

KW - Angiogenesis

KW - Cancer/molecular biology

KW - Metastasis

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84903852837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903852837&partnerID=8YFLogxK

U2 - 10.4161/cbt.28882

DO - 10.4161/cbt.28882

M3 - Article

C2 - 24755674

AN - SCOPUS:84903852837

VL - 15

SP - 919

EP - 929

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 7

ER -